We are transforming drug manufacturing, starting with insulin
rBIO has developed a proprietary manufacturing process designed to increase drug-production output and support a licensing-first model, beginning with insulin.
Our platform combines proprietary process IP and manufacturing know-how to improve the economics of essential peptide drugs and prepare the company for regional and global licensing partnerships.
The problem
Complex manufacturing drives high drug prices
Diabetes has reached epidemic levels, yet insulin cost and supply remain unstable. One reason is that peptide-drug manufacturing remains complex, expensive, and difficult to scale efficiently.
rBIO is focused on the manufacturing problem behind drug pricing. The company’s proprietary process is designed to increase insulin output and create a more efficient path for qualified partners to manufacture essential peptide drugs.
Insulin first
Process-ready to license
Designed for regional and global manufacturing partners
We’re working to change the economics of drug manufacturing.
Our first focus: insulin
rBIO is applying its proprietary manufacturing process first to insulin, where manufacturing efficiency, cost, and supply stability remain urgent market issues.
The company has completed early development work, including 20L pilot work and an exploratory animal study, and is preparing for the next major scale-up milestone: optimization at 1,000L.
Insulin-first strategy
20L pilot – completed
Exploratory animal study – completed
1,000L scale-up planned
Process-ready to license
A proprietary process designed to double output
rBIO’s platform combines proprietary manufacturing process IP and technical know-how to increase peptide-drug production output, beginning with insulin.
The company’s goal is to complete scale-up and make the process available through licensing to qualified regional and strategic partners.
A licensing model for scalable access
rBIO’s business model is designed to help qualified partners manufacture essential peptide drugs more efficiently. The company intends to license insulin first, expand globally, and then extend the platform to additional peptides over time.
We’re building a process.
We’re preparing it to scale.
